Published in Gene Therapy Weekly, June 26th, 2003
The findings from the study were presented at the annual American Society of Clinical Oncology (ASCO) conference in Chicago.
Frank G. Haluska, MD, PhD, at the Massachusetts General Hospital Cancer Center, was the lead investigator of the phase I/II trial and presented the clinical results.
"Data from this clinical trial further demonstrate that vaccine immunization approaches in cancer can be safe and effective in creating measurable immune responses in some patients with melanoma," stated Haluska. "While there are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.